Dyne Therapeutics (DYN) Accumulated Expenses (2019 - 2026)

Dyne Therapeutics' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $29.2 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 520.19% year-over-year to $29.2 million; the TTM figure through Mar 2026 stood at $29.2 million (up 520.19% YoY), while the FY2025 annual figure was $17.1 million, up 30.56% from the prior year.
• Accumulated Expenses was $29.2 million for Q1 2026 at Dyne Therapeutics, up from $17.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $29.2 million in Q1 2026 to a low of $1.4 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $11.2 million across 5 years, with a median of $10.5 million in 2023.
• Biggest YoY gain for Accumulated Expenses was 727.22% in 2022; the steepest drop was 80.29% in 2022.
• A 5-year view of Accumulated Expenses shows it stood at $18.2 million in 2022, then slumped by 42.38% to $10.5 million in 2023, then grew by 24.74% to $13.1 million in 2024, then soared by 30.56% to $17.1 million in 2025, then jumped by 70.85% to $29.2 million in 2026.
• The last three Accumulated Expenses figures came in at $29.2 million (Q1 2026), $17.1 million (Q4 2025), and $13.2 million (Q3 2025), per Business Quant data.